Pathway Genomics CancerIntercept Detect Blood Testing Class Action Lawsuit Investigation
Investigating a class action lawsuit on behalf of individuals who paid for Pathway Genomics' CancerIntercept(TM) Detect blood test. Pathway market's this as the "cancer stethoscope." It is the only liquid biopsy that is sold directly to consumers. In September 2015, the Food and Drug Administration (FDA) sent Pathway a letter saying it was “offering a high risk test that has not received adequate clinical validation and may harm the public health.” Pathway recently informed the LA Times that the company had responded to the FDA's concerns and has “limited the claims of what their test does to ones that seem to be more in line with the current available evidence.” If you have purchased Pathway's CancerIntercept(TM) Detect blood test, please contact us. |
|